Proposed Data Collections Submitted for Public Comment and Recommendations, 18554-18555 [2011-7886]
Download as PDF
18554
Federal Register / Vol. 76, No. 64 / Monday, April 4, 2011 / Notices
Daniel Holcomb,
Reports Clearance Officer, Centers for Disease
Control and Prevention.
collection activity is proposed through
this project to collect information about
behavioral and clinical outcomes from
injection drug users, high-risk
heterosexuals, and HIV-positive
individuals who access medical care in
six of the 12 ECHPP-funded MSAs.
These MSAs are: District of Columbia;
Houston, TX; Los Angeles, CA; Miami,
FL; New York City, NY; and San
Francisco, CA. The purpose of this new
data collection activity is to monitor
community-level outcomes of ECHPP
and supplement HIV surveillance data
routinely collected in these areas.
Outcome data will be collected in these
MSAs at two time points from 2011 to
2014.
Two surveys will be used in this
project: (1) A community-based survey
to be administered to injection drug
users and high-risk heterosexuals, and
(2) a clinic-based survey to be
administered to HIV-positive
individuals seeking care at clinics that
provide HIV-related services. Both
surveys will collect data on
demographics, sexual behavior, alcohol
and drug use history, HIV testing
experiences, exposure to HIV
prevention messages, and participation
in HIV prevention activities. The clinic
survey will also include questions about
HIV treatment, treatment adherence,
sources of care, and medical outcomes.
For the community survey, we intend to
recruit and screen 1500 injection drug
users and 1500 high-risk heterosexuals
using venue-based, convenience
sampling methods. For the clinic
survey, we intend to recruit and screen
2400 HIV-positive individuals seeking
HIV care at medical clinics. A total of
1200 eligible injection drug users (age ≥
18 yrs), 1200 eligible high-risk
heterosexuals (age 18 to 60 yrs), and
2400 eligible HIV-positive individuals
(age ≥ 18 yrs) will be surveyed. CDC will
collaborate with local health department
staff and outreach workers in each MSA
to identify venues and clinics
appropriate for data collection. Surveys
will be administered by trained, local
interviewers. There is no cost to
respondents other than their time.
New-National Center for HIV/AIDS,
Viral Hepatitis, STD, and TB Prevention
(NCHHSTP), Centers for Disease Control
and Prevention (CDC).
[FR Doc. 2011–7888 Filed 4–1–11; 8:45 am]
BILLING CODE 4163–18–P
Background and Brief Description
The scope of the HIV epidemic in the
United States is significant, particularly
in large urban areas where HIV/AIDS
cases are concentrated. In 2006,
approximately 56,000 new HIV
infections occurred in the U.S.,
demonstrating the need to expand
targeted HIV prevention efforts. In 2010,
twelve U.S. metropolitan statistical
areas (MSAs) received funding, through
their city and state health departments,
to conduct the Enhanced
Comprehensive HIV Prevention
Planning (ECHPP) project. These twelve
MSAs (Atlanta, GA; Baltimore, MD;
Chicago, IL; Dallas, TX; District of
Columbia; Houston, TX; Los Angeles,
CA; Miami, FL; New York City, NY;
Philadelphia, PA; San Francisco, CA;
and San Juan, PR) had the highest AIDS
prevalence rates in the U.S. at the end
of 2007, representing 44% of all U.S.
AIDS cases. The purpose of ECHPP is to
enhance existing HIV prevention
services in these high prevalence areas
and provide an optimal mix of
evidence-based behavioral, biomedical,
and structural interventions to have
maximum impact on the HIV/AIDS
epidemic at the community level.
ECHPP goals are consistent with CDC’s
Division of HIV/AIDS Prevention
Strategic Plan for HIV Prevention and
with the National HIV/AIDS Strategy:
(1) Prevent new HIV infections, (2)
increase linkage to, and impact of,
prevention and care services for HIVpositive individuals, and (3) reduce
HIV-related health disparities.
To evaluate ECHPP, data will be
collected through both existing CDC
data sources and through new data
collection activities. Existing CDC data
sources will include HIV surveillance
systems (e.g., National HIV Behavioral
Surveillance System, Medical
Monitoring Project) that routinely
collect information about behavioral
and clinical outcomes from at-risk target
populations in the 12 MSAs. A new data
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day-11–11DT]
Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–5960 or send
comments to Daniel Holcomb, CDC
Reports Clearance Officer, 1600 Clifton
Road, MS–D74, Atlanta, GA 30333 or
send an e-mail to omb@cdc.gov.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.
Proposed Project
Monitoring Outcomes of the
Enhanced Comprehensive HIV
Prevention Planning (ECHPP) Project-
Emcdonald on DSK2BSOYB1PROD with NOTICES
ESTIMATE OF ANNUALIZED BURDEN TABLE
Number of
respondents
Target population
Data collection form
Injection drug users ............................................
Eligible injection drug users ................................
High-risk heterosexual individuals ......................
Eligible high-risk heterosexual individuals ..........
HIV-positive individuals .......................................
Community Screener ......
Community Survey .........
Community Screener ......
Community Survey .........
Clinic Screener ...............
VerDate Mar<15>2010
18:47 Apr 01, 2011
Jkt 223001
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
500
400
500
400
933
E:\FR\FM\04APN1.SGM
1
1
1
1
1
04APN1
Average
burden per
response
(in hours)
5/60
25/60
5/60
25/60
5/60
Total burden
(in hours)
42
167
42
167
78
18555
Federal Register / Vol. 76, No. 64 / Monday, April 4, 2011 / Notices
ESTIMATE OF ANNUALIZED BURDEN TABLE—Continued
Number of
responses per
respondent
Number of
respondents
Average
burden per
response
(in hours)
Total burden
(in hours)
Target population
Data collection form
Eligible HIV-positive individuals ..........................
Clinic Survey ..................
800
1
25/60
333
Total .............................................................
.........................................
........................
........................
........................
829
[FR Doc. 2011–7882 Filed 4–1–11; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4163–18–P
Dated: March 29, 2011.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
BILLING CODE 4163–18–P
[FR Doc. 2011–7886 Filed 4–1–11; 8:45 am]
Dated: March 29, 2011.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2011–7883 Filed 4–1–11; 8:45 am]
Daniel Holcomb,
Reports Clearance Officer, Centers for Disease
Control and Prevention.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Centers for Medicare & Medicaid
Services
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
Statement of Organization, Functions,
and Delegations of Authority
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
Emcdonald on DSK2BSOYB1PROD with NOTICES
The meeting announced below
concerns Virologic Evaluation of the
Modes of Influenza Virus Transmission
among Humans, Funding Opportunity
Announcement (FOA), IP11–001, initial
review.
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting:
Time and Date: 8 a.m.–5 p.m., May 17,
2011 (Closed).
Place: Sheraton Gateway Hotel Atlanta
Airport, 1900 Sullivan Road, Atlanta, Georgia
30337, Telephone: (770) 997–1100.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c)(4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters to be Discussed: The meeting will
include the initial review, discussion, and
evaluation of applications received in
response to ‘‘Virologic Evaluation of the
Modes of Influenza Virus Transmission
among Humans, FOA IP11–001.’’
Contact Person for More Information:
Gregory Anderson, M.S., M.P.H., Scientific
Review Officer, CDC, 1600 Clifton Road, NE.,
Mailstop E60, Atlanta, Georgia 30333,
Telephone: (404) 498–2293.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
VerDate Mar<15>2010
18:47 Apr 01, 2011
Jkt 223001
The meeting announced below
concerns Economic Studies of Vaccines
and Immunization Policies, Programs,
and Practices, Funding Opportunity
Announcement (FOA), IP11–007, initial
review.
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the aforementioned meeting:
Time and Date: 12 p.m.–2 p.m., June 14,
2011 (Closed).
Place: Teleconference.
Status: The meeting will be closed to the
public in accordance with provisions set
forth in Section 552b(c) (4) and (6), Title 5
U.S.C., and the Determination of the Director,
Management Analysis and Services Office,
CDC, pursuant to Public Law 92–463.
Matters to be Discussed: The meeting will
include the initial review, discussion, and
evaluation of applications received in
response to ‘‘Economic Studies of Vaccines
and Immunization Policies, Programs, and
Practices, FOA IP11–007, initial review.’’
Contact Person for More Information: Amy
Yang, PhD, Scientific Review Officer, CDC,
1600 Clifton Road, NE., Mailstop E60,
Atlanta, Georgia 30333, Telephone: (404)
498–2733.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
Part F of the Statement of
Organization, Functions, and
Delegations of Authority for the
Department of Health and Human
Services, Centers for Medicare &
Medicaid Services (CMS), (Federal
Register, Vol. 75, No. 56, pp. 14178,
dated Wednesday, March 24, 2010) is
amended to reflect updates to the
functions for the Center for Strategic
Planning (FCK).
Part F. is described below:
• Section FC. 20. (Functions) reads as
follows:
Center for Strategic Planning (FCK)
• Provide senior leadership over the
strategic planning process and the
development of CMS strategic goals,
metrics, and plans.
• Direct the development of financial
and health care trend analysis and
management insight report to inform
senior CMS leadership strategic
decision making.
• Set priorities for CSP direction,
budget, personnel, and staff
development.
• Translate statistical data into
information useful to agency leadership.
• Provide leadership to the
development of performance
dashboards and databases for key
agency initiatives.
• Provide leadership in maintaining
and ensuring quality of data resources
needed for testing and evaluating
demonstrations and innovations.
• Direct the development of
enterprise business plans, process
requirement for CMS post ACA
E:\FR\FM\04APN1.SGM
04APN1
Agencies
[Federal Register Volume 76, Number 64 (Monday, April 4, 2011)]
[Notices]
[Pages 18554-18555]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-7886]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-11-11DT]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
copy of the data collection plans and instruments, call 404-639-5960 or
send comments to Daniel Holcomb, CDC Reports Clearance Officer, 1600
Clifton Road, MS-D74, Atlanta, GA 30333 or send an e-mail to
omb@cdc.gov.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology. Written comments should be received
within 60 days of this notice.
Proposed Project
Monitoring Outcomes of the Enhanced Comprehensive HIV Prevention
Planning (ECHPP) Project-New-National Center for HIV/AIDS, Viral
Hepatitis, STD, and TB Prevention (NCHHSTP), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
The scope of the HIV epidemic in the United States is significant,
particularly in large urban areas where HIV/AIDS cases are
concentrated. In 2006, approximately 56,000 new HIV infections occurred
in the U.S., demonstrating the need to expand targeted HIV prevention
efforts. In 2010, twelve U.S. metropolitan statistical areas (MSAs)
received funding, through their city and state health departments, to
conduct the Enhanced Comprehensive HIV Prevention Planning (ECHPP)
project. These twelve MSAs (Atlanta, GA; Baltimore, MD; Chicago, IL;
Dallas, TX; District of Columbia; Houston, TX; Los Angeles, CA; Miami,
FL; New York City, NY; Philadelphia, PA; San Francisco, CA; and San
Juan, PR) had the highest AIDS prevalence rates in the U.S. at the end
of 2007, representing 44% of all U.S. AIDS cases. The purpose of ECHPP
is to enhance existing HIV prevention services in these high prevalence
areas and provide an optimal mix of evidence-based behavioral,
biomedical, and structural interventions to have maximum impact on the
HIV/AIDS epidemic at the community level. ECHPP goals are consistent
with CDC's Division of HIV/AIDS Prevention Strategic Plan for HIV
Prevention and with the National HIV/AIDS Strategy: (1) Prevent new HIV
infections, (2) increase linkage to, and impact of, prevention and care
services for HIV-positive individuals, and (3) reduce HIV-related
health disparities.
To evaluate ECHPP, data will be collected through both existing CDC
data sources and through new data collection activities. Existing CDC
data sources will include HIV surveillance systems (e.g., National HIV
Behavioral Surveillance System, Medical Monitoring Project) that
routinely collect information about behavioral and clinical outcomes
from at-risk target populations in the 12 MSAs. A new data collection
activity is proposed through this project to collect information about
behavioral and clinical outcomes from injection drug users, high-risk
heterosexuals, and HIV-positive individuals who access medical care in
six of the 12 ECHPP-funded MSAs. These MSAs are: District of Columbia;
Houston, TX; Los Angeles, CA; Miami, FL; New York City, NY; and San
Francisco, CA. The purpose of this new data collection activity is to
monitor community-level outcomes of ECHPP and supplement HIV
surveillance data routinely collected in these areas. Outcome data will
be collected in these MSAs at two time points from 2011 to 2014.
Two surveys will be used in this project: (1) A community-based
survey to be administered to injection drug users and high-risk
heterosexuals, and (2) a clinic-based survey to be administered to HIV-
positive individuals seeking care at clinics that provide HIV-related
services. Both surveys will collect data on demographics, sexual
behavior, alcohol and drug use history, HIV testing experiences,
exposure to HIV prevention messages, and participation in HIV
prevention activities. The clinic survey will also include questions
about HIV treatment, treatment adherence, sources of care, and medical
outcomes. For the community survey, we intend to recruit and screen
1500 injection drug users and 1500 high-risk heterosexuals using venue-
based, convenience sampling methods. For the clinic survey, we intend
to recruit and screen 2400 HIV-positive individuals seeking HIV care at
medical clinics. A total of 1200 eligible injection drug users (age >=
18 yrs), 1200 eligible high-risk heterosexuals (age 18 to 60 yrs), and
2400 eligible HIV-positive individuals (age >= 18 yrs) will be
surveyed. CDC will collaborate with local health department staff and
outreach workers in each MSA to identify venues and clinics appropriate
for data collection. Surveys will be administered by trained, local
interviewers. There is no cost to respondents other than their time.
Estimate of Annualized Burden Table
----------------------------------------------------------------------------------------------------------------
Average
Data collection Number of Number of burden per Total burden
Target population form respondents responses per response (in (in hours)
respondent hours)
----------------------------------------------------------------------------------------------------------------
Injection drug users.......... Community 500 1 5/60 42
Screener.
Eligible injection drug users. Community Survey 400 1 25/60 167
High-risk heterosexual Community 500 1 5/60 42
individuals. Screener.
Eligible high-risk Community Survey 400 1 25/60 167
heterosexual individuals.
HIV-positive individuals...... Clinic Screener. 933 1 5/60 78
[[Page 18555]]
Eligible HIV-positive Clinic Survey... 800 1 25/60 333
individuals.
---------------------------------------------------------------------------------
Total..................... ................ .............. .............. .............. 829
----------------------------------------------------------------------------------------------------------------
Daniel Holcomb,
Reports Clearance Officer, Centers for Disease Control and Prevention.
[FR Doc. 2011-7886 Filed 4-1-11; 8:45 am]
BILLING CODE 4163-18-P